Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

Transplantation

Volumn 90, Issue 8, 2010, Pages 905-911

  Dey, Bimalangshu R ^a   Chung, Stephen S ^a   Spitzer, Thomas R ^a   Zheng, Hui ^a   MacGillivray, Thomas E ^a   Seldin, David C ^b   McAfee, Steven ^a   Ballen, Karen ^a   Attar, Eyal ^a   Wang, Thomas ^a   Shin, Jordan ^a   Newton Cheh, Christopher ^a   Moore, Stephanie ^a   Sanchorawala, Vaishali ^b   Skinner, Martha ^b   Madsen, Joren C ^a   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid; Cardiac amyloidosis; Stem cell transplantation

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; DIURETIC AGENT; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THALIDOMIDE; VALGANCICLOVIR; ALANINE; ASPARTATE AMINOTRANSFERASE; CARDIOTONIC AGENT;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; FLUID RETENTION SYNDROME; FOLLOW UP; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; LEG EDEMA; LIGHT CHAIN AMYLOIDOSIS; LOW DRUG DOSE; MALE; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SIDE EFFECT; SURVIVAL; WEIGHT; AUTOTRANSPLANTATION; BLOOD; HEART STROKE VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MORTALITY; STEM CELL TRANSPLANTATION;

ADULT; AGED; ALANINE; AMYLOIDOSIS; ASPARTATE AMINOTRANSFERASES; CARDIOTONIC AGENTS; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; STEM CELL TRANSPLANTATION; STROKE VOLUME; TRANSPLANTATION, AUTOLOGOUS;

EID: 78249290790     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f10edb     Document Type: Article

References (20)

1. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290.
2. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202.
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45.
4. Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262.
5. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloid-osis: An 8-year study. Ann Intern Med 2004; 140: 85.
6. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025.
7. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: A case-control study. Blood 2004; 103: 3960.
8. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257.
9. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immuno-globulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141.
10. Hosenpud JD. Restrictive cardiomyopathy. In: Zipes DP, Rowlands DJ, eds. Progress in Cardiology. Philadelphia, Lea & Febiger 1989, pp 91.
11. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999; 24: 853.
12. Conner R, Hosenpud JD, Norman DJ, et al. Heart transplantation for cardiac amyloidosis: Successful one-year outcome despite recurrence of the disease. J Heart Transplant 1988; 7: 165.
13. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amy-loidosis undergoing heart transplantation. Follow-up results of a mul-ticenter survey. Circulation 1991; 84: III338.
14. Dubrey SW, Burke MM, Hawkins PN,etal. Cardiac transplantation for amyloid heart disease: The United Kingdom experience. J Heart Lung Transplant 2004; 23: 1142.
15. Kpodonu J, Massad MG, Caines A, et al. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005; 24: 1763.
16. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007; 110: 3561.
17. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107: 1227.
18. Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopa-thy. J Heart Lung Transplant 2008; 27: 823.
19. Burzynski JA, Dispenzieri A, Gertz MA, et al. Fluid-related complications in patients with amyloidosis associated with filgrastim during peripheral blood stem cell mobilization. ASH Annual Meeting Abstracts 2004; 104: 1143.
20. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexa-methasone. Haematologica 2007; 92: 1351.